Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor. The purpose of this study was to evaluate the effect of adding tocilizumab to disease-modifying antirheumatic drug (DMARD) therapy for the treatment of rheumatoid arthritis (RA).We performed a meta-analysis of relevant randomized controlled trials (RCTs) identified in PubMed, Cochrane library, and Embase. The primary efficacy outcome was the proportion of patients with a 20
作者:Mao Mao, An;Zui, Zou;Hui, Shen;Jun Dong, Zhang;Yong Bing, Cao;Yuan Ying, Jiang
来源:European journal of clinical pharmacology 2010 年 66卷 1期